高级检索
    齐一凡, 钟文昭, 张嘉涛. 更上一层楼——奥希替尼辅助治疗完全切除的EGFR基因突变阳性非小细胞肺癌患者: ADAURA[J]. 循证医学, 2022, 22(1): 19-25. DOI: 10.12019/j.issn.1671-5144.2022.01.005
    引用本文: 齐一凡, 钟文昭, 张嘉涛. 更上一层楼——奥希替尼辅助治疗完全切除的EGFR基因突变阳性非小细胞肺癌患者: ADAURA[J]. 循证医学, 2022, 22(1): 19-25. DOI: 10.12019/j.issn.1671-5144.2022.01.005
    shu
    QI Yi-fan, ZHONG Wen-zhao, ZHANG Jia-tao. The Next Level: ADAURA, Adjuvant Osimertinib in Completely Resected EGFR-Mutated Non-Small-Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2022, 22(1): 19-25. DOI: 10.12019/j.issn.1671-5144.2022.01.005
    Citation: QI Yi-fan, ZHONG Wen-zhao, ZHANG Jia-tao. The Next Level: ADAURA, Adjuvant Osimertinib in Completely Resected EGFR-Mutated Non-Small-Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2022, 22(1): 19-25. DOI: 10.12019/j.issn.1671-5144.2022.01.005
    shu

    更上一层楼——奥希替尼辅助治疗完全切除的EGFR基因突变阳性非小细胞肺癌患者: ADAURA

    The Next Level: ADAURA, Adjuvant Osimertinib in Completely Resected EGFR-Mutated Non-Small-Cell Lung Cancer

      摘要
      • HTML全文
      • 参考文献(35)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回